References
- Bai C, Connolly B, Metzker ML, et al. (2000) Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. PNAS 97:1230–1235.
- Brown LM, Hoover R, Silverman D, et al. (2001) Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol 153:114–122.
- Chang YC, Chan YH, Jackson DG, et al. (2006) The glycosaminoglycan-binding domain of decoy receptor 3 is essential for induction of monocyte adhesion. J Immunol. (Baltimore, Md: 1950) 176:173–180.
- Chang YC, Hsu TL, Lin HH, et al. (2004) Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol 75:486–494.
- Enzinger PC, Mayer RJ. (2003) Esophageal cancer. N Engl J Med 349:2241–52.
- Greene FL, Page DL, Fleming ID, et al. (2002) AJCC Cancer Staging Manual. 6th Edition. New York: Springer.
- Hsu TL, Chang YC, Chen SJ, et al. (2002) Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol(Baltimore, Md: 1950) 168:4846–4853.
- Jemal A, Siegel R, Ward E, et al. (2008) Cancer statistics. CA Cancer J Clin 58:71–96.
- Kamangar F, Dores GM, Anderson WF. (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150.
- Macher-Goeppinger S, Aulmann S, Wagener N, et al. (2008) Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 10:1049–1056.
- Migone TS, Zhang J, Luo X, et al. (2002) TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16:479–492.
- Ohshima K, Haraoka S, Sugihara M, et al. (2000) Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer Lett 160:89–97.
- Pickens A, Orringer MB. (2003) Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg 76:S1367–1369
- Pitti RM, Marsters SA, Lawrence DA, et al. (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699–703.
- Roth W, Isenmann S, Nakamura M, et al. (2001) Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 61:2759–2765.
- Shi G, Wu Y, Zhang J, et al. (2003) Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo. J Immunol. (Baltimore, Md: 1950) 171:3407–3414.
- Simon I, Liu Y, Krall KL, et al. (2007) Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol 106:112–118.
- Stoner GD, Gupta A. (2001) Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 22:1737–46.
- Takahama Y, Yamada Y, Emoto K, et al. (2002) The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 5:61–68.
- Tsuji S, Hosotani R, Yonehara S, et al. (2003) Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Int J Cancer 106:17–25.
- Wan X, Shi G, Semenuk M, et al. (2003) DcR3/TR6 modulates immune cell interactions. J Cell Biochem 89:603–612.
- Wu Y, Guo E, Yu J, et al. (2008) High DcR3 expression predicts stage pN2-3 in gastric cancer. Am J Clin Oncol 31:79–83.
- Wu Y, Han B, Sheng H, et al. (2003) Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer 105:724–732.
- Yu KY, Kwon B, Ni J, et al. (1999) A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 274:13733–13736.
- Zhang J, Salcedo TW, Wan X, et al. (2001) Modulation of T-cell responses to alloantigens by TR6/DcR3. J Clin Invest 107:1459–1468.